Research from the Faculty of Medicine Siriraj Hospital "Innovative combination of resveratrol (RES), a phenolic compound with sunitinib ...

Research from the Faculty of Medicine Siriraj Hospital "Innovative combination of resveratrol (RES), a phenolic compound with sunitinib (SUNI), a tyrosine kinase inhibitor, to target colon cancer cells.”

Synergistic anticancer activity of resveratrol-loaded polymeric nanoparticles and sunitinib in colorectal cancer treatment

Abstract

Developing new and effective treatment strategies Especially through the use of various drugs together. It can significantly increase treatment results. This study explores an innovative combination of resveratrol (RES), a phenolic compound, and sunitinib (SUNI), a multi-targeted tyrosine kinase inhibitor. To target human colon adenocarcinoma cell line HT-29, we found a synergistic effect at a SUNI:RES ratio of 1:8 based on the half-maximal inhibitory concentration. Increasing the combined treatment dose led to a marked decrease in cell viability. This was observed in both two-dimensional (2D) and three-dimensional cell cultures. To improve the therapeutic efficacy of RES, we successfully created drug-loaded polymer nanoparticles (PLGA-RES) with an average diameter of 178.4 ± 4.6 nm by combining PLGA-RES and free SUNI in an appropriate ratio. Shows increased anti-cancer activity It reduced cell viability by approximately 25% and 15% more than free PLGA-RES and SUNI alone, respectively, in 2D culture. Moreover, This combination therapy also demonstrated superior efficacy in treating HT-29 spheroid cells over a 24- and 48-hour period. These findings highlight the potential of this combined approach to improve colorectal cancer treatment outcomes.